CAH Treatment: New Steroid Options & Pump Therapy Explained

Refining Treatment for Congenital Adrenal Hyperplasia: New Approaches to Cortisol Management

For individuals living with congenital adrenal hyperplasia (CAH), maintaining the right balance of cortisol is a lifelong challenge. Traditional treatments, relying on oral steroids, often struggle to mimic the body’s natural cortisol rhythms, leading to fluctuations that can impact energy levels, mood, and overall health. However, emerging therapies are aiming to address these difficulties, offering more precise and personalized approaches to hormone replacement. These include modified-release steroids available in Europe and, closer to home for some, continuous subcutaneous hydrocortisone infusion – often called steroid pump therapy.

Understanding the Cortisol Challenge in CAH

CAH is a group of inherited disorders that affect the adrenal glands, leading to a deficiency in cortisol production. Cortisol is a vital hormone regulating many bodily functions, including stress response, metabolism, and immune function. Individuals with CAH must take daily cortisol replacement medication to compensate for this deficiency. The difficulty lies in replicating the natural, fluctuating cortisol levels the body produces throughout the day. Traditional oral steroids deliver a consistent dose, which can result in peaks that are too high and troughs that are too low, according to Sasan Mirfakhraee, MD, an associate professor in the division of endocrinology at UT Southwestern Medical Center in Dallas.

Modified-Release Hydrocortisone: A European Option

Currently available only in Europe, Efmody and Plenadren represent a step towards more natural cortisol replacement. These oral medications are designed to be modified-release forms of hydrocortisone, meaning the body breaks them down and clears them from the system more slowly. This slower release aims to provide a more gradual rise and fall in cortisol levels, better mirroring the body’s natural rhythm. This approach potentially allows for fewer daily doses, simplifying treatment regimens. However, as noted by experts, You’ll see no current plans for the U.S. Food and Drug Administration (FDA) to approve these medications for use in the United States.

Steroid Pump Therapy: Mimicking the Body’s Natural Rhythm

Continuous subcutaneous hydrocortisone infusion (CSHI), or steroid pump therapy, offers another avenue for achieving more physiological cortisol delivery. Similar in concept to an insulin pump, these devices deliver liquid hydrocortisone under the skin through a small tube. The pump can be programmed to release hydrocortisone at varying rates throughout the day, closely mimicking the body’s natural cortisol rhythm. Dr. Mirfakhraee explains that this approach “generally allows for a lower total daily dose of steroid and improved symptoms such as energy and mood.”

Evidence for Steroid Pump Therapy: Improved Well-being, but with Risks

Research, including a retrospective study conducted at UT Southwestern Medical Center, supports the potential benefits of CSHI. The study, published in PubMed, examined 33 individuals with adrenal insufficiency who were offered a trial of CSHI due to persistent symptoms. Results showed a decrease in the total daily dose of glucocorticoid, a reduction in emergency department visits and hospitalizations related to adrenal crisis, and a numerical increase in subjective health scores. Specifically, the median number of ED visits due to adrenal crisis decreased from 0.5 per year to zero after switching to CSHI. However, CSHI is not without risks. A pump malfunction, if unnoticed, can interrupt hydrocortisone delivery, potentially leading to a life-threatening adrenal crisis.

Navigating the Risks and Benefits of CSHI

While CSHI shows promise, Dr. Mirfakhraee emphasizes the need for further research to fully understand the balance between its benefits and risks compared to traditional treatments. The decision to use a steroid pump is highly individualized and requires careful consideration of a patient’s specific needs and circumstances. Currently, the FDA has not approved these devices, meaning doctors prescribe them “off-label” – for a purpose other than what the device was originally approved for. This practice is legal, but it means the long-term safety and efficacy data are less robust than for FDA-approved treatments.

The Importance of Individualized CAH Management

CAH management is complex and requires a collaborative approach between patients and their healthcare team. The goal is to find a treatment regimen that effectively controls symptoms, minimizes side effects, and improves quality of life. The emergence of modified-release steroids and steroid pump therapy represents a significant step forward in achieving this goal, offering more personalized options for cortisol replacement. However, it’s crucial to remember that these therapies are not one-size-fits-all and require careful monitoring and adjustment to ensure optimal outcomes.

Future Directions in CAH Treatment

Research continues to explore new and improved therapies for CAH. Ongoing studies are investigating novel drug formulations, gene therapy approaches, and more refined methods for monitoring cortisol levels. The ultimate aim is to develop treatments that can restore normal adrenal function and eliminate the need for lifelong hormone replacement. For now, individuals with CAH and their healthcare providers can function together to navigate the available options and create a treatment plan that best meets their individual needs. It is important to stay informed about the latest research and guidance from organizations like the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).